Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A Snaith is active.

Publication


Featured researches published by A Snaith.


American Journal of Cardiovascular Drugs | 2008

The Potential for Interaction between Warfarin and Coprescribed Medication : A Retrospective Study in Primary Care

A Snaith; Lyn Pugh; Colin R Simpson; James S. McLay

Background and objectiveWarfarin is commonly involved in drug-related hospital admissions. The drug is most commonly prescribed to elderly patients in whom polypharmacy is common and, when administered in combination with other drugs such as NSAIDs, aspirin (acetylsalicylic acid) or macrolide antibacterials, is associated with increased bleeding risk. The aim of this study was to investigate the prevalence of prescriptions that might give rise to clinically relevant drug-drug interactions in a warfarinized population.MethodsPrimary care prescribing of warfarin and potentially interacting medicines was assessed between 1 April 2005 and 31 March 2006 using computerized prescribing data retrieved from 321 primary care practices in Scotland.ResultsA total of 17 861 registered patients were prescribed warfarin in the study year, of whom 68% (n = 12 107) were concomitantly issued with a prescription for at least one potentially interacting medicine. For short-term use, ‘one-off’ prescriptions for antibacterials (sulfonamides, ciprofloxacin, and macrolides), nonselective NSAIDs and antithrombotics (fibrinolytics) were the most frequently prescribed drug groups with potential for interaction, being prescribed to 12.7%, 5.3%, and 1.4% of warfarinized patients, respectively. Macrolide antibacterials were prescribed in significantly fewer warfaranized patients than standardized population (3.84% vs 4.41%; p < 0.001). For long-term use, nonselective NSAIDs and antithrombotics were the most frequently prescribed drug groups, being prescribed to 21.0% and 21.1% of warfarinized patients, respectively. When compared with a standardized population, NSAIDs and antithrombotics were prescribed to a significantly smaller proportion of the warfarin population, whereas selective cyclo-oxygenase 2 inhibitors were prescribed to a significantly greater proportion. Nevertheless for the whole warfarinized population 26.3% were prescribed nonselective NSAIDs and 22.5% antithrombotic agents.ConclusionsThe lower ‘one off’ use of macrolide antibacterials and long-term use of antithrombotics and NSAIDs in warfarinized patients observed in this study might suggest awareness among general practitioners of the increased risks for bleeding associated with concomitant use of these agents with warfarin therapy. However, despite this, the majority of warfarinized patients in this study were issued with a repeat prescription for at least one potentially interacting medicine.


Health Technology Assessment | 2010

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.

E. Cummins; Pamela Royle; A Snaith; A. Greene; Lynn Robertson; Linda McIntyre; Norman Waugh


Cochrane Database of Systematic Reviews | 2011

Glucagon‐like peptide analogues for type 2 diabetes mellitus

Deepson Shyangdan; Pamela Royle; Christine Clar; Pawana Sharma; Norman Waugh; A Snaith


Health Technology Assessment | 2012

Non-Pharmacological Interventions to Reduce the Risk of Diabetes in People with Impaired Glucose Regulation: A Systematic Review and Economic Evaluation

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh


British Journal of Clinical Pharmacology | 2007

Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey

Derek Stewart; Abdul Rouf; A Snaith; Kathleen Elliott; Peter J. Helms; James S. McLay


Archive | 2012

Studies excluded from the systematic review of clinical effectiveness

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh


Archive | 2012

Prevalence of type 2 diabetes mellitus in ethnic minorities

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh


Archive | 2012

Systematic review of clinical effectiveness

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh


Archive | 2012

Modifiable risk factors for type 2 diabetes mellitus

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh


Archive | 2012

Potential further sensitivity analyses

M Gillett; Pamela Royle; A Snaith; Graham Scotland; A Poobalan; Mari Imamura; C Black; M Boroujerdi; S Jick; Laura Wyness; Paul McNamee; Alan Brennan; N Waugh

Collaboration


Dive into the A Snaith's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Laura Wyness

British Nutrition Foundation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

N Waugh

University of Warwick

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alan Brennan

University of Sheffield

View shared research outputs
Top Co-Authors

Avatar

M Gillett

University of Sheffield

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge